Ardsley Advisory Partners grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 42.9% in the 4th quarter, Holdings Channel reports. The firm owned 10,000 shares of the biotechnology company’s stock after purchasing an additional 3,000 shares during the quarter. Ardsley Advisory Partners’ holdings in BioMarin Pharmaceutical were worth $892,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bain Capital Public Equity Management LLC boosted its stake in BioMarin Pharmaceutical by 60.5% in the 4th quarter. Bain Capital Public Equity Management LLC now owns 391,576 shares of the biotechnology company’s stock worth $34,917,000 after purchasing an additional 147,531 shares during the period. Ellington Management Group LLC purchased a new stake in BioMarin Pharmaceutical during the 4th quarter valued at $749,000. Stone Ridge Asset Management LLC purchased a new stake in BioMarin Pharmaceutical during the 4th quarter valued at $2,738,000. Argentiere Capital AG raised its holdings in BioMarin Pharmaceutical by 11.1% during the 4th quarter. Argentiere Capital AG now owns 50,000 shares of the biotechnology company’s stock valued at $4,459,000 after buying an additional 5,000 shares during the period. Finally, Fred Alger Management Inc. raised its holdings in BioMarin Pharmaceutical by 0.4% during the 4th quarter. Fred Alger Management Inc. now owns 1,024,032 shares of the biotechnology company’s stock valued at $91,313,000 after buying an additional 3,793 shares during the period.
Several analysts recently weighed in on the company. BMO Capital Markets restated an “outperform” rating and set a $125.00 price target (up previously from $119.00) on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Wedbush reiterated an “outperform” rating and issued a $110.00 target price on shares of BioMarin Pharmaceutical in a research note on Friday, December 22nd. SunTrust Banks increased their target price on BioMarin Pharmaceutical to $130.00 and gave the stock a “buy” rating in a research note on Monday, December 11th. Zacks Investment Research lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Sunday, February 25th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. BioMarin Pharmaceutical presently has an average rating of “Buy” and an average price target of $112.34.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.06). The firm had revenue of $358.31 million for the quarter, compared to analysts’ expectations of $346.24 million. BioMarin Pharmaceutical had a negative net margin of 8.91% and a negative return on equity of 3.18%. analysts forecast that BioMarin Pharmaceutical Inc. will post -0.67 EPS for the current year.
In other news, Director Elaine J. Heron sold 800 shares of the firm’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $88.90, for a total transaction of $71,120.00. Following the transaction, the director now owns 38,385 shares in the company, valued at $3,412,426.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jean Jacques Bienaime sold 20,000 shares of the firm’s stock in a transaction on Friday, December 29th. The shares were sold at an average price of $89.75, for a total value of $1,795,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 101,655 shares of company stock worth $9,069,499. Insiders own 1.85% of the company’s stock.
WARNING: This story was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.themarketsdaily.com/2018/03/13/ardsley-advisory-partners-grows-stake-in-biomarin-pharmaceutical-inc-bmrn.html.
BioMarin Pharmaceutical Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.